Boreal Genomics raises $18M to support Dx test and genomic tool expansion

California's Boreal Genomics pulled in an $18 million Series C financing to back further commercial growth of its genomic research tools and diagnostic test business. The Los Altos company sells research tools and develops diagnostic tests focused on noninvasive tumor profiling and cancer monitoring. A core focus: genomic analysis of tumor-derived circulating nucleic acids in blood. And execs want to roll out new blood-based diagnostic tests to help detect and monitor disease. Existing investors ARCH Venture Partners and Kearny Venture Partners participated in the new round, which also attracted unnamed strategic and private investors. Boreal launched in 2007 and employs about 40 people. Story

Suggested Articles

Digital molecule designer Insilico Medicine has launched a new preclinical research program focused on treatments for brain cancer.

Ortho Clinical Diagnostics has launched a new chemistry system to complete its integrated Vitros XT line of laboratory solutions.

Synthetic DNA weaver Twist Bioscience announced a handful of new collaborations this week amidst a $140 million raise from an underwritten offering.